Significant single-agent activity in diffuse large B-cell lymphoma (DLBCL) cell models and in mouse model showed superiority to lenalidomide (Revlimid®)...
Agency assigns PDUFA action date of May 8, 2023 MydCombi™, if approved, would be the first product incorporating Eyenovia’s novel...
ERAS-3490, an orally available small molecule KRAS G12C inhibitor, has demonstrated robust nonclinical CNS and systemic activitySAN DIEGO, Dec. 13,...
Accomplished scientist with a diverse range of skills from general wet lab technique to company-wide operations managementOCALA, Fla., Dec. 12,...
--FemCerv®, the first endocervical tissue sampler of its kind in the detection of cervical cancer, was well-received after being presented...
Oral presentation further details positive data from mavorixafor Phase 1b clinical trial in people with chronic idiopathic, cyclic, or congenital...
CINCINNATI, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a...
MONTRÉAL, Dec. 12, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation,...
Media Release Event to be held live in New Orleans, LouisianaMeeting to be webcast live and archived on www.genmab.com Copenhagen,...
Los Gatos, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company today announced the...
STAR-LLD, a continuous delivery system of lenalidomide in development by Starton Therapeutics, was recently evaluated in a preclinical efficacy study...
BMF-500, an investigational third generation covalent FLT3 inhibitor, demonstrated preclinically: Picomolar affinity to activating FLT3 mutations including FLT3-ITD and various...
CAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to...
DARE-PDM1 Utilizes Proprietary Hydrogel Technology for Vaginal Delivery of Diclofenac, a Nonsteroidal Anti-Inflammatory; Phase 1 Study Targeted for 2023 2022...
Highlights: Phase 1/2 trial of RECCE® 327 (R327) is approved to start at the South West Sydney Limb Preservation and...
LOS ANGELES, CA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company...
Company Provides Comprehensive Clinical Update from Phase 1/2 TrialTuspetinib Continues to Deliver Single Agent Responses in r/r AML PatientsTuspetinib Safety...
– ASH poster presentation summarizes preclinical data from SENTI-202, an off-the-shelf CAR-NK cell therapy candidate engineered with a logic-gated gene...
The HAVEN 7 study was designed to further confirm the benefit of preventative treatment (prophylaxis) with Hemlibra from birth in...
-- Preliminary study results show that tifcemalimab is well-tolerated at all administered doses. The observed clinical activity of tifcemalimab in...